Literature DB >> 11314710

Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation.

S S Chandrasekhar1.   

Abstract

OBJECTIVE: To discuss the value of intratympanic dexamethasone (IT-DEX) perfusion for sudden sensorineural hearing loss (SSNHL), clinically and in an animal model. STUDY
DESIGN: Retrospective case review of 10 patients with SSNHL treated with IT-DEX. The findings are correlated with this institution's previous findings from a study of IT-DEX in guinea pigs.
SETTING: Ambulatory tertiary otologic referral center. PATIENTS: Sequential patients with SSNHL who chose IT-DEX treatment.
INTERVENTIONS: Dexamethasone 0.5 mg was injected transtympanically and bathed the round window for 20 minutes. Animal study: 79 ears were randomized into five groups: control, IT-DEX versus intravenous (IV)-DEX, IT-DEX with histamine, IT-DEX with hyaluronic acid, and IT-DEX with dimethylsulfoxide. MAIN OUTCOME MEASURES: Clinical study: postprocedure audiometry. Animal study: perilymph steroid concentration.
RESULTS: IT-DEX results in significant hearing improvement and in significantly higher perilymph concentration of steroid than IV-DEX.
CONCLUSIONS: IT-DEX is an appropriate treatment option for the treatment of SSNHL. Further study of dosages and frequency of administration is warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314710     DOI: 10.1097/00129492-200101000-00005

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  58 in total

1.  Acute Hearing Loss.

Authors:  Madhura Tamhankar; David Solomon
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

2.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

3.  [Intratympanic glucocorticoid therapy of sudden hearing loss].

Authors:  S K Plontke
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

Review 4.  Local inner-ear drug delivery and pharmacokinetics.

Authors:  Alec N Salt; Stefan K R Plontke
Journal:  Drug Discov Today       Date:  2005-10-01       Impact factor: 7.851

Review 5.  Intratympanic steroid therapy for inner ear diseases, a review of the literature.

Authors:  M J R C Alles; M A der Gaag; R J Stokroos
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

6.  A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia.

Authors:  Hee-Jun Kim; Eun-Kyung Park; In-Seok Moon
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

7.  Transtympanic corticoid therapy for acute profound hearing loss.

Authors:  Jürgen Lautermann; Holger Sudhoff; Rüdiger Junker
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-03       Impact factor: 2.503

8.  Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy.

Authors:  Haralampos Gouveris; Oksana Selivanova; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-04-29       Impact factor: 2.503

Review 9.  Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature.

Authors:  Tomás Labatut; María José Daza; Antonio Alonso
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-20       Impact factor: 2.503

10.  Transtympanic steroids in refractory sudden hearing loss. Personal experience.

Authors:  I Dallan; L Bruschini; A Nacci; B Fattorp; A C Traino; F Rognini; G Ferraro; P Bruschini
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-02       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.